水文连通对于维护滨海湿地生物多样性至关重要,鱼类多样性作为生物多样性的重要组成部分,了解其对不同水文连通强度的响应具有重要意义。本研究基于环境DNA宏条形码技术(e DNA metabarcoding)检测黄河三角洲典型潮沟系统鱼类多样性,分...水文连通对于维护滨海湿地生物多样性至关重要,鱼类多样性作为生物多样性的重要组成部分,了解其对不同水文连通强度的响应具有重要意义。本研究基于环境DNA宏条形码技术(e DNA metabarcoding)检测黄河三角洲典型潮沟系统鱼类多样性,分析鱼类物种分布对不同水文连通强度潮沟生境差异的响应特征。利用12S r RNA经典鱼类引物对采集自三级潮沟系统的水样进行高通量测序,共检测出鱼类55种,其中本地鱼类27种、非本地鱼类28种,物种组成以鲈形目为主。各样点序列丰度均较高的鱼类有矛尾刺虾虎鱼(Acanthogobius hasta)、鮻(Planiliza haematocheilus)、长体刺虾虎鱼(Acanthogobius elongatus)等。鱼类多样性在不同水文连通性潮沟间差异明显,其中,二级潮沟群落多样性水平、丰富度指数、物种种类及各种鱼类类群中的个体均匀程度等都明显高于其他两级潮沟。RDA分析显示有6种环境因子与鱼类群落结构显著相关(P<0.05),分别为:硅酸盐(SiO_(3)^(2-)-Si)、硝酸盐(NO_(3)^(-)-N)、酸碱度(p H值)、盐度(SAL)、铵盐(NH_(4)^(+)–N)、溶解氧(DO)。其中,优势种矛尾刺虾虎鱼的序列丰度与硅酸盐呈正相关,鮻的序列丰度与盐度呈负相关。本研究通过与传统采样数据进行比较,证实了环境DNA宏条形码技术用于监测黄河口典型潮沟水体中鱼类多样性的可行性,表明潮沟系统水文连通性对鱼类群落结构及多样性均具有明显的影响,研究结果有助于进一步了解滨海湿地水文连通对生物群落的影响机制。展开更多
Objective: The purpose of this study was to analyze the relationship between signal transducer and activator of transcription 3 (STAT3) and carcinoembryonic antigen (CEA) in lung adenocarcinoma cell A549, and to explo...Objective: The purpose of this study was to analyze the relationship between signal transducer and activator of transcription 3 (STAT3) and carcinoembryonic antigen (CEA) in lung adenocarcinoma cell A549, and to explore the value of STAT3 on early diagnosis of lung adenocarcinoma. Methods: The expression of CEA, STAT3 mRNA and it's protein in human lung adenocarcinoma cell A549 and normal human lung cells MRC-5 were tested by immunohistochemistry staining (PV) and quantitative real time fluorescent PCR. The correlation between STAT3 and CEA in human lung adenocarcinoma cell A549 was analyzed. Results: The protein and mRNA levels of STAT3, CEA in lung adenocarcinoma cell A549 were apparently higher than those in normal human lung cells MRC-5. The levels of STAT3 mRNA and it's protein were positively correlated with CEA in lung adenocarcinoma cell A549. Conclusion: STAT3 have the same value in diagnosis of lung adenocarcinoma.展开更多
Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin...Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting.展开更多
文摘水文连通对于维护滨海湿地生物多样性至关重要,鱼类多样性作为生物多样性的重要组成部分,了解其对不同水文连通强度的响应具有重要意义。本研究基于环境DNA宏条形码技术(e DNA metabarcoding)检测黄河三角洲典型潮沟系统鱼类多样性,分析鱼类物种分布对不同水文连通强度潮沟生境差异的响应特征。利用12S r RNA经典鱼类引物对采集自三级潮沟系统的水样进行高通量测序,共检测出鱼类55种,其中本地鱼类27种、非本地鱼类28种,物种组成以鲈形目为主。各样点序列丰度均较高的鱼类有矛尾刺虾虎鱼(Acanthogobius hasta)、鮻(Planiliza haematocheilus)、长体刺虾虎鱼(Acanthogobius elongatus)等。鱼类多样性在不同水文连通性潮沟间差异明显,其中,二级潮沟群落多样性水平、丰富度指数、物种种类及各种鱼类类群中的个体均匀程度等都明显高于其他两级潮沟。RDA分析显示有6种环境因子与鱼类群落结构显著相关(P<0.05),分别为:硅酸盐(SiO_(3)^(2-)-Si)、硝酸盐(NO_(3)^(-)-N)、酸碱度(p H值)、盐度(SAL)、铵盐(NH_(4)^(+)–N)、溶解氧(DO)。其中,优势种矛尾刺虾虎鱼的序列丰度与硅酸盐呈正相关,鮻的序列丰度与盐度呈负相关。本研究通过与传统采样数据进行比较,证实了环境DNA宏条形码技术用于监测黄河口典型潮沟水体中鱼类多样性的可行性,表明潮沟系统水文连通性对鱼类群落结构及多样性均具有明显的影响,研究结果有助于进一步了解滨海湿地水文连通对生物群落的影响机制。
文摘Objective: The purpose of this study was to analyze the relationship between signal transducer and activator of transcription 3 (STAT3) and carcinoembryonic antigen (CEA) in lung adenocarcinoma cell A549, and to explore the value of STAT3 on early diagnosis of lung adenocarcinoma. Methods: The expression of CEA, STAT3 mRNA and it's protein in human lung adenocarcinoma cell A549 and normal human lung cells MRC-5 were tested by immunohistochemistry staining (PV) and quantitative real time fluorescent PCR. The correlation between STAT3 and CEA in human lung adenocarcinoma cell A549 was analyzed. Results: The protein and mRNA levels of STAT3, CEA in lung adenocarcinoma cell A549 were apparently higher than those in normal human lung cells MRC-5. The levels of STAT3 mRNA and it's protein were positively correlated with CEA in lung adenocarcinoma cell A549. Conclusion: STAT3 have the same value in diagnosis of lung adenocarcinoma.
基金China National Major Project for New Drug Innovation,Grant/Award Number:2017ZX09304015Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS),Grant/Award Number:2016-I2M-1-001。
文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting.
